|1.||De Broe, Marc E: 7 articles (02/2009 - 03/2004)|
|2.||D'Haese, Patrick C: 6 articles (02/2009 - 03/2004)|
|3.||Behets, Geert J: 5 articles (02/2009 - 07/2004)|
|4.||Drüeke, Tilman B: 4 articles (02/2012 - 03/2005)|
|5.||Lacour, Bernard: 3 articles (02/2012 - 03/2005)|
|6.||Verberckmoes, Steven C: 3 articles (02/2009 - 07/2004)|
|7.||Guo, Fei: 2 articles (10/2015 - 08/2010)|
|8.||Li, Min: 2 articles (09/2013 - 03/2009)|
|9.||Gao, Guo Dong: 2 articles (09/2013 - 03/2009)|
|10.||Qu, You Zhi: 2 articles (09/2013 - 03/2009)|
11/28/2009 - "Some reports show that lanthanum, a rare earth element, induces apoptosis in certain cancer cells. "
06/15/2007 - "Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)."
03/01/2005 - "Blood tumor permeability of experimental brain tumor: an electron microscopic study using lanthanum."
07/01/1987 - "Effects of hyperthermia and lanthanum on tumor cell leakage."
01/01/1985 - "Intracellular ionic changes during hyperthermia of tumor cells in the presence of lanthanum."
01/01/2010 - "Lanthanum (La) carbonate is a new treatment for hyperphosphatemia. "
11/01/2008 - "However, recent evidence in CKD patients and the absence of solid arguments for any particular rat organ toxicity, suggest that lanthanum is safe and efficient in treatment of hyperphosphatemia. "
01/01/2015 - "Treatment with lanthanum was independently associated with a significant survival benefit in hemodialysis patients with inadequately controlled hyperphosphatemia. "
08/01/2009 - "Lanthanum, a rare earth element, has been used to decrease serum phosphorus level in patients with chronic renal disease and hyperphosphatemia. "
07/01/2003 - "Shire Pharmaceuticals Group plc, under exclusive license from AnorMED Inc (a subsidiary of Johnson Matthey), is developing lanthanum carbonate, a phosphate-binding lanthanum salt, for the potential treatment of hyperphosphatemia in dialysis patients. "
12/01/1977 - "After 1 h and 15 min of hypoxia, abnormal intracellular lanthanum accumulation was associated with only minimal ultrastructural evidence of injury; muscle provided reoxygenation after 1 h and 15 min of hypoxia showed improved ultrastructure and did not exhibit intracellular lanthanum deposits upon exposure to lanthanum during the reoxygenation period. "
12/01/1977 - "Lanthanum probe studies of cellular pathophysiology induced by hypoxia in isolated cardiac muscle."
04/01/1984 - "These findings suggest that hypoxia may not be associated with increased vascular membrane permeability to lanthanum, as has been reported by some workers to occur with more severe metabolic deprivation."
04/01/1984 - "Extracellular space measurements using radioisotope markers (35S-sulphate and 14C-sorbitol) and ultrastructural examination of lanthanum distribution have been carried out on two vascular tissues (aorta, portal vein) exposed to normoxic and hypoxic media to see if hypoxia is associated with membrane damage. "
12/01/1977 - "Thus, the data support the conclusion that cellular and membrane alterations responsible for abnormal intracellular lanthanum deposition precede the development of irreversible injury but evolve at a transitional stage in the progression from reversible to irreversible injury induced by hypoxia in isolated feline papillary muscles."
09/01/1984 - "Lanthanum, which inhibits Ca influx both via the slow Ca channel and via Na-Ca exchange, delayed onset of contracture if added after exposure to CN and 2DG, but accelerated contracture if added prior to treatment with CN + 2DG. "
01/01/1996 - "Although reperfusion reversed injury in some cells, in general, myocytes exhibited myofibrillar contracture, while membrane integrity recovered to some extent, as indicated by reduced lanthanum influx. "
02/01/1991 - "(1) Oxidative stress resulted in irreversible contracture and impairment of sarcolemmal integrity revealed by using the transmembrane tracer ionic lanthanum. "
04/01/1990 - "Hearts developed full contracture by 15-18 min at which time most myocytes were contracted and retained lanthanum intracellularly. "
04/01/1990 - "At 50% contracture lanthanum influx into contracted cells became more frequent. "
02/01/2003 - "Absence of a functional iNOS gene in iNOSKO mice resulted in a significant reduction of apical diffusion of lanthanum after DNBS-induced colitis. "
10/01/1997 - "Experimental colitis is associated with hepatobiliary complications and an increased hepatocyte tight junctional permeability to horseradish peroxidase and lanthanum. "
07/01/2002 - "Absence of a functional IL-10 gene in IL-10KO mice resulted in a significant augmentation of apical diffusion of lanthanum after DNBS-induced colitis. "
10/01/1997 - "Colitis was associated with increased serum bilirubin and bile acid concentrations, a 2.5-fold increase in paracellular biliary excretion of horseradish peroxidase, and a ninefold increase in lanthanum permeability. "
|2.||2,4-dinitrofluorobenzene sulfonic acid
|3.||lanthanum carbonate (Fosrenol)
|1.||Electric Power Supplies (Power Supply)
|5.||Renal Dialysis (Hemodialysis)